AR and prostate carcinoma: Since 5α-reductase inhibitors change the testosterone-to-DHT ratio, and given the critical role of 5α-reductase in AR signaling, the different 5α-reductase expression levels may provide clues about response and resistance to 5α-reductase inhibitors in prostate cancer prevention.